---
trial_id: 170
discovery_date: 2022-03-20 17:40:25.855903
date: 2022-03-20 17:40:25.855903
title: "Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis"
summary: |
  <b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Ocrelizumab;   Drug: Placebo for Ocrelizumab<br /><b>Sponsors</b>:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence (ACE)<br /><b>Not yet recruiting</b>
link: 'https://clinicaltrials.gov/ct2/show/NCT05285891?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14'
published_date: 2022-03-18 16:00:00
trial_source: ClinicalTrials.gov
relevant: 
options:
  unlisted: false
---
<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Biological: Ocrelizumab;   Drug: Placebo for Ocrelizumab<br /><b>Sponsors</b>:    National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence (ACE)<br /><b>Not yet recruiting</b>